BCRX — BIOCRYST PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 882796 ·
Last close
$7.50
Market Cap
$1.93B
52W High
$11.22
52W Low
$6.23
ADV30
5,237,027
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 180,292,000 | 178,718,000 | 53,330,000 | 37,916,000 | 591,070,000 | 96,971,000 | 988,454,000 |
| Jun 2026 | 218,250,000 | 214,410,000 | 98,465,000 | 78,395,000 | 557,851,000 | 154,972,000 | 1,012,140,000 |
| Mar 2026 | 156,413,000 | 151,036,000 | -701,598,000 | -721,812,000 | 465,052,000 | 171,591,000 | 1,018,895,000 |
| Dec 2025 | 406,555,000 | 397,033,000 | 260,385,000 | 245,845,000 | 514,158,000 | 89,736,000 | 633,311,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$367,494,000
Investing CF
$-541,159,000
Financing CF
$171,363,000
CapEx
$-1,647,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.42
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,111,680,000
Inventory
$13,740,000
Receivables
$121,786,000
ST Investments
$278,027,000
EBIT TTM
$-277,921,000
Pretax Income TTM
$-354,732,000
Interest Exp TTM
$76,811,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$961,510,016
EBITDA
$472,468,000
Free Cash Flow
$301,088,256
Enterprise Value
$2,431,832,320
Total Cash
$374,998,016
Total Debt
$828,198,976
Shares Out
257,299,269
Trailing EPS
$-1.28
Book Value
$-1.55
ROE
—
ROA
56.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 874,837,000 | 340,989,000 | 263,861,000 | 514,158,000 | 633,311,000 | -119,153,000 | 347,369,000 |
| Dec 2024 | 450,712,000 | -2,543,000 | -88,881,000 | 490,420,000 | 966,354,000 | -475,934,000 | -52,020,000 |
| Dec 2023 | 331,412,000 | -103,709,000 | -226,539,000 | 516,960,000 | 972,488,000 | -455,528,000 | -95,141,000 |
| Dec 2022 | 270,827,000 | -148,435,000 | -247,116,000 | 550,000,000 | 844,597,000 | -294,597,000 | -161,850,000 |
TTM Snapshot
Revenues TTM
$940,613,000
NetIncome TTM
$-384,673,000
OpCashFlow TTM
—
Assets (Latest)
$557,851,000
Forward EPS
$0.82
Max Pain — expiry 2026-12-18
max pain strike: $8.00 · spot: $7.30 · call oi: 6,230 · put oi: 1,186
Expected Move to 2026-12-18:
±$0.92
(12.60%) —
implied range
$6.38 –
$8.22
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| REPL | Replimune Group, Inc. | $1.87B | $19.69 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.83B | $39.06 | — |
| MAZE | Maze Therapeutics, Inc. | $1.80B | $32.87 | — |
| BEAM | Beam Therapeutics Inc. | $2.14B | $20.65 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.69B | $2.72 | — |
News headlines (Yahoo Finance, 1h cache)
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
2026-11-13 12:00 · Yahoo
The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
2026-11-11 06:36 · Yahoo
BioCryst Pharmaceuticals (BCRX) Raised Its Outlook, Is It Still Below Fair Value?
2026-11-07 07:11 · Yahoo
BioCryst Pharmaceuticals Inc (BCRX) (Q3 2026) Earnings Call Highlights: ORLADEYO Revenue Climbs ...
2026-11-05 09:07 · Yahoo
BioCryst to Present at Upcoming Investor Conferences
2026-11-04 21:01 · Yahoo
BioCryst (BCRX) Q3 2026 Earnings Call Transcript
2026-11-04 17:30 · Yahoo
BioCryst Pharmaceuticals Q3 Earnings Call Highlights
2026-11-04 16:14 · Yahoo
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
2026-11-04 12:55 · Yahoo
BioCryst: Q3 Earnings Snapshot
2026-11-04 12:22 · Yahoo
BioCryst Reports Third Quarter 2026 Financial Results
2026-11-04 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.